Bohdan J Kudryk

6451599, Sep 17, 2002

Apr 13, 2000

09/548895

Alessandra Bini - Astoria NY
Bohdan J. Kudryk - Hillside NJ

New York Blood Center - New York NY

C07K 1636

435337, 435 71, 435 724, 435 792, 435 13, 435 691, 435 7021, 436514, 436516, 436518, 436524, 436528, 436529, 436530, 436531, 436534, 436536, 436538, 436548, 436172, 5303873, 53038825, 5303911, 5303913

The invention provides monoclonal antibodies which are reactive with fibrin(ogen) degradation products (FDPS) generated by matrix metalloproteinases (MMPs), such as MMP-3, MMP-7, and membrane-type 1, MT1-MMP proteolysis of fibrinogen and cross-linked fibrin (and not plasmin or other proteases). Monoclonal antibodies of the invention include, but are not limited to, H5, F2, 90/2, 90/5, B4, 13, C6, A6, G6, E6, 197-1 and 197-2. This invention also provides methods of using monoclonal antibodies for detection of FDPs generated by proteolysis of fibrin(ogen) by MMPs, such as MMP-3, MMP-7, and MT1-MMP. In addition, the present invention provides methods for diagnosing rheumatoid arthritis, osteoarthritis, and synovitides, as well as angiogenesis, atherosclerosis, renal diseases, malignancy and inflammation. The present invention also provides methods for diagnosing fibrin formation and degradation in physiological processes such as in wound healing deficiencies and abnormalities, and in development of human placenta and in pregnancy diseases.

60254769, Feb 15, 2000

Oct 6, 1998

9/167647

Gerd Grieninger - New York NY
Yiping Fu - New York NY
Yan Cao - Valhalla NY
Mohamad Zaher Ahadi - Paterson NJ
Bohdan J. Kudryk - Hillsdale NJ

New York Blood Center, Inc. - New York NY

C07K 1600

5303881

The invention provides monospecific antibodies which are specifically reactive with the. alpha. sub. E subunit of fibrinogen or a fragment thereof, but not with other portions of the fibrinogen molecule. The invention also provides anti-. alpha. sub. E probes, including monospecific anti-. alpha. sub. E antibodies which have been detectably labeled. In addition, the invention provides methods of using the monospecific antibodies for detection of the. alpha. sub. E subunit and fragments thereof, as well as reagents and kits for performing the methods. Diagnostic methods for determining information associated with atherogenesis and/or thrombogenesis, as well as for determining information associated with pregnancy status or outcome. The invention further provides continuous cell lines which produce monospecific anti-. alpha. sub. E antibodies.

48513342, Jul 25, 1989

Aug 10, 1987

7/084002

Bohdan J. Kudryk - Little Ferry NJ
Michael E. Wiebe - Stamford CT

The New York Blood Center, Inc. - New York NY

C07K 1504
A61K 39395
G01N 33577
C12N 510

435 7

Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B. beta. chain of human fibrinogen or fibrin I containing amino acid residues 1-42. The hybridoma is formed by fusing an animal myeloma cell, e. g. , mouse myeloma cell, with a splenocyte from an animal, e. g. , a mouse, immunized with an NH. sub. 2 -terminal of human fibrinogen or fibrin I. Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B. beta. chain of human fibrin II containing amino acid residues 15-42. The hybridoma is formed by fusing an animal, e. g. , mouse myeloma cell with a splenocyte from an animal, e. g. , mouse, immunized with a NH. sub. 2 -terminal of human fibrin II. Diagnostic and therapeutic uses of the monoclonal antibodies are also disclosed.

47229039, Feb 2, 1988

Jan 3, 1984

6/567462

Bohdan J. Kudryk - Little Ferry NJ
Michael E. Wiebe - Stamford CT

New York Blood Center, Inc. - New York NY

G01N 33577
C12N 500
C07K 1504

435 7

Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B. beta. chain of human fibrinogen or fibrin I containing amino acid residues 1-42. The hybridoma is formed by fusing an animal myeloma cell, e. g. , a mouse myeloma cell, with a splenocyte from an animal, e. g. , a mouse, immunized with an NH. sub. 2 -terminal of human fibrinogen or fibrin I. Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B. beta. chain of human fibrin II containing amino acid residues 15-42. The hybridoma is formed by fusing an animal, e. g. , mouse myeloma cell with a splenocyte from an animal, e. g. , mouse, immunized with a NH. sub. 2 -terminal of human fibrin II. Diagnostic and therapeutic uses of the monoclonal antibodies are also disclosed.

58177680, Oct 6, 1998

Jun 7, 1995

8/479755

Gerd Grieninger - New York NY
Yiping Fu - New York NY
Yan Cao - Valhalla NY
Mohamad Zaher Ahadi - Paterson NJ
Bohdan J. Kudryk - Hillsdale NJ

The New York Blood Center, Inc. - New York NY

C07K 1600
C07K 1700
C12P 2108

5303881

The invention provides nonspecific antibodies which are specifically reactive with the. alpha. sub. E subunit of fibrinogen or a fragment thereof, but not with other portions of the fibrinogen molecule. The invention also provides anti-. alpha. sub. E probes, including nonspecific anti-. alpha. sub. E antibodies which have been detectably labeled. In addition, the invention provides methods of using the nonspecific antibodies for detection of the. alpha. sub. E subunit and fragments thereof, as well as reagents and kits for performing the methods. Diagnostic methods for determining information associated with atherogenesis and/or thrombogenesis, as well as for determining information associated with pregnancy status or outcome. The invention further provides continuous cell lines which produce monospecific anti-. alpha. sub. E antibodies.

58769471, Mar 2, 1999

Jul 25, 1997

8/900660

Bohdan J. Kudryk - Hillsdale NJ
Colvin M. Redman - Franklin Square NY
Jian-Zhong Zhang - New York NY

The New York Blood Center, Inc. - New York NY

G01N 3353
G01N 33543
G01N 33536
C07K 1636

435 71

The invention provides monospecific antibodies that are specifically reactive with fibrinopeptide B (FPB) and with fibrinogen and fragments thereof containing the amino acid sequence defined by SEQ ID NO:1. The invention also provides anti-FPB probes, including monospecific anti-FPB antibodies that have been detectably labeled. In addition, the invention provides methods of using the monospecific antibodies for detection of fibrinopeptide B, as well as reagents and kits for performing the methods. For example, the invention provides a method for detecting fibrinopeptide B with specificity in biological samples such as blood samples, by using the antibody to immunometrically bind to the fibrinopeptide B. Diagnostic methods for determining information associated with atherogenesis and/or thrombogenesis. The invention further provides continuous cell lines (hybridomas) that produce monospecific anti-FPB antibodies.

60430877, Mar 28, 2000

Jul 25, 1997

8/900895

Alessandra Bini - New York NY
Bohdan J. Kudryk - Hillsdale NJ

The New York Blood Center - New York NY

C12N 520
C07K 1636
G01N 33543
G01N 33544

435337

The invention provides a monospecific antibody that is specifically reactive with enzymatically mediated degradation products of fibrin(ogen) (i. e. , fibrin, fibrinogen, and related substances). The monospecific antibody of the invention is specifically reactive with an epitope defined by an amino acid sequence SEQ ID NO:1. The invention further provides compositions containing a monospecific antibody, optionally detectably labeled, for the performance of fibrinolytic or thrombolytic analyses. The invention further provides continuous cell lines (hybridomas) that produce monospecific antibodies as described.

60251484, Feb 15, 2000

Jul 1, 1997

8/886269

Gerd Grieninger - New York NY
Yiping Fu - New York NY
Yan Cao - Valhalla NY
Mohamad Zaher Ahadi - Paterson NJ
Bohdan J. Kudryk - Hillsdale NJ

New York Blood Center, Inc. - New York NY

C07K 1600

435 792

The invention provides monospecific antibodies which are specifically reactive with the. alpha. hd E subunit of fibrinogen or a fragment thereof, but not with other portions of the fibrinogen molecule. The invention also provides anti-. alpha. sub. E probes, including monospecific anti-. alpha. sub. E antibodies which have been detectably labeled. In addition, the invention provides methods of using the monospecific antibodies for detection of the. alpha. sub. E subunit and fragments thereof, as well as reagents and kits for performing the methods. Diagnostic methods for determining information associated with atherogenesis and/or thrombogenesis, as well as for determining information associated with pregnancy status or outcome. The invention further provides continuous cell lines which produce monospecific anti-. alpha. sub. E antibodies.